All Type of News
Asthma drug, Xolair, introduced as prefilled syringe
The asthma treatment which has not been able to pass the wall of the health insurance since its approval in 2007, Xolair(generic name: omalizumab), was introduced as a prefilled syringe type.
According to the Ministr...
Metal materials detected in antibiotics imported by Abbott KoreaAs metal materials were detected in antibiotics imported by Abbott Korea, they were ordered to be recalled and suspended in usage.
On the 25th, the Ministry of Food and Drug Sa...
|
Followed by Keytruda, Opdivo completed in landing into ‘Big 5’ hospitals
‘Opdivo,’ an immunotherapy cooperated by BMS and Ono Pharmaceutical, entered Seoul National University Hospital, completing the landing process into the ‘Big 5’ hospitals.
According to the industry concerned on the ...
GSK decreasing number of employees while enlarging directors’ salariesGlaxoSmithKline(GSK), which tightened up the financial status through laying off 176 employees last year, was observed, on the other hand, to increase the amount of compensation...
|
Japan’s ‘anticancer-CNS’ vs Korea’s ‘anticancer-antidiabetic’
The current environment of the Korean pharmaceutical industry is evaluated as similar to the Japanese 1990s in many aspects, such as the amount of sales, the R&D development steps and the government’s drug pricing pol...
Is the biopharmaceutical field just like chasing a mirage?
It was recently analyzed the biopharmaceutical industry has not enough capability to be responsible for the future of a nation, although interests in the industry is explosive. Particularly, it is expected that its gr...
Rare disease drugs will be consigned for manufacturing by domestic pharmaceutical companies
Domestic pharmaceutical companies will be able to consign manufacturing of rare disease drugs and pharmaceutical products that are promptly required to be introduced in Korea.
On the 24th, the Ministry of Food and Dr...
Upturn of obesity treatments even in 1st quarter considered as off-season
The obesity treatment market which has been depressed for a while has recently taken an upturn from the introduction of new drugs.
Since ‘Belviq(Ildong Pharmaceutical),’ the new obesity therapy which acquired approva...
Lilly and Samsung fueled competition in biosimilar insulin market
Biosimilar developers will now aim for the insulin market. Their target is ‘Lantus,’ the one prescribed the most.
According to the industry concerned on the 24th, the first biosimilar of Lantus(insulin glargine) was...
Will Multaq fly in antiarrhythmic market with removal of insurance standard condition?
The Sanofi’s antiarrhythmic drug ‘Multaq(generic name: dronedarone)’ seems to be easy on its usage in the clinical field due to relaxation of the health insurance standard.
The Ministry of Health and Welfare(MOHW) ga...
